Skip to main content
Clinical Trials/JPRN-UMIN000045411
JPRN-UMIN000045411
Not yet recruiting
未知

Observational study to investigate the correlations between the circulating tumor DNA and clinicopathological features of metastatic lesion - Observational study to investigate the correlations between the circulating tumor DNA and clinicopathological features of metastatic lesion

ational Research and Development Agency, National Cancer Center0 sites100 target enrollmentOctober 1, 2021

Overview

Phase
未知
Intervention
Not specified
Conditions
colorectal cancer
Sponsor
ational Research and Development Agency, National Cancer Center
Enrollment
100
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 1, 2021
End Date
December 31, 2022
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Exclusion criteria for the prospective cohort 1\. Active overlapping cancers noted at the time of curative resection. However, patients with a recurrence\-free period of at least 5 years; those with basal cell carcinoma or spinous cell carcinoma of the skin that was eventually cured after receiving local treatment; and those with superficial bladder cancer, cervical cancer, carcinoma in situ, intramucosal cancer (that can be treated endoscopically), and nonmetastatic prostate cancer (that does not require systematic treatment) can be registered. 2\. Pre\-operative treatment (chemotherapy, radiation therapy, immunotherapy) is administered or planned prior to metastasis resection Exclusion criteria for the retrospective cohort 1\. Active overlapping cancers noted at the time of curative resection. \*However, patients with a recurrence\-free period of at least 5 years or those with basal cell carcinoma or spinous cell carcinoma of the skin that was eventually cured by local treatment, superficial bladder cancer, cervical cancer, carcinoma in situ (that can be treated endoscopically), and nonmetastatic prostate cancer (that does not require systematic treatment) can be registered. 2\. Pre\-operative treatment (chemotherapy, radiation therapy, immunotherapy) was administered prior to the curative resection of metastases. \*\*Adjuvant chemotherapy administered prior to the appearance of metastases is acceptable.

Outcomes

Primary Outcomes

Not specified

Similar Trials